IMR Press / EJGO / Volume 36 / Issue 3 / DOI: 10.12892/ejgo2610.2015

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Case Report
Addition of bevacizumab to neoadjuvant chemotherapy for Stage IV ovarian serous adenocarcinoma with multiple lymph node metastases: a case report
H. Liu1,†Y. Shi1,†G. N. Zhang1,*S. Q. Song1T. Hu1
Show Less
1 Department of Gynecological Oncology, Sichuan Cancer Hospital, Chengdu (China)
These authors contributed equally.
Eur. J. Gynaecol. Oncol. 2015, 36(3), 341–345; https://doi.org/10.12892/ejgo2610.2015
Published: 10 June 2015
Abstract

A 50-year-old female patient was diagnosed with Stage IV ovarian serous adenocarcinoma with multiple lymph node metastases. The CA-125 level normalized after four cycles of neoadjuvant chemotherapy (NACT) using paclitaxel, nedaplatin, and bevacizumab (BEV) before surgery. A positron emission tomography-computed tomography (PET-CT) scan showed significantly reduced bilateral adnexal masses after NACT fluorodeoxyglucose (FDG) metabolism in multiple lymph nodes was inhibited significantly, and the number and sites of metastatic lesions were decreased. The patient underwent optimal cytoreductive surgery. Chemotherapy was continued after surgery and image-guided radiation therapy (IGRT) (40 Gy) was applied for the remaining lymph nodes in the pelvic cavity and cervicothoracic region. No sign of recurrence has been observed in this patient nine months after surgery. The patient achieved a satisfactory outcome and no serious side effects were observed. Therefore, addition of BEV to NACT is a new method for the pre-operative treatment of advanced ovarian cancer.
Keywords
Advanced ovarian cancer
Neoadjuvant chemotherapy
Bevacizumab
Share
Back to top